NSD2 contributes to oncogenic RAS-driven transcription in lung cancer cells through long-range epigenetic activation
The histone methyltransferase NSD2/WHSC1/MMSET is overexpressed in a number of solid tumors but its contribution to the biology of these tumors is not well understood. Here, we describe that NSD2 contributes to the proliferation of a subset of lung cancer cell lines by supporting oncogenic RAS trans...
| Autores: | , , , , , , , , , |
|---|---|
| Tipo de recurso: | artículo |
| Fecha de publicación: | 2016 |
| País: | España |
| Institución: | Instituto de Salud Carlos III (ISCIII) |
| Repositorio: | Repisalud |
| Idioma: | inglés |
| OAI Identifier: | oai:repisalud.isciii.es:20.500.12105/8572 |
| Acceso en línea: | http://hdl.handle.net/20.500.12105/8572 |
| Access Level: | acceso abierto |
| Palabra clave: | Animals Azepines Benzamides Cell Line, Tumor Cell Proliferation Diphenylamine Enhancer Elements, Genetic Enzyme Inhibitors Epigenesis, Genetic Gene Expression Gene Knockdown Techniques Histone-Lysine N-Methyltransferase Histones Humans Lung Neoplasms MAP Kinase Kinase Kinases Methylation Mice Mice, Nude Nuclear Proteins Repressor Proteins Transcription Factors Transcription, Genetic Triazoles Xenograft Model Antitumor Assays Genes, ras |
| Sumario: | The histone methyltransferase NSD2/WHSC1/MMSET is overexpressed in a number of solid tumors but its contribution to the biology of these tumors is not well understood. Here, we describe that NSD2 contributes to the proliferation of a subset of lung cancer cell lines by supporting oncogenic RAS transcriptional responses. NSD2 knock down combined with MEK or BRD4 inhibitors causes co-operative inhibitory responses on cell growth. However, while MEK and BRD4 inhibitors converge in the downregulation of genes associated with cancer-acquired super-enhancers, NSD2 inhibition affects the expression of clusters of genes embedded in megabase-scale regions marked with H3K36me2 and that contribute to the RAS transcription program. Thus, combinatorial therapies using MEK or BRD4 inhibitors together with NSD2 inhibition are likely to be needed to ensure a more comprehensive inhibition of oncogenic RAS-driven transcription programs in lung cancers with NSD2 overexpression. |
|---|